OBJECTIVE: Periconceptional use of @entity1501 can prevent @entity600 , including at least 50% of @entity601 . This study used an ongoing surveillance system to explore the association between pregnancy intendedness and @entity1 taking periconceptional @entity1501 . METHODS: Oregon Pregnancy Risk Assessment Monitoring System (PRAMS) surveys a stratified random sample of @entity1 after a live birth. In 1998-1999, 1867 @entity1 completed the survey (64.0% response rate); responses were weighted for nonresponse. @entity1 were asked whether they took @entity1501 most days in the month before becoming pregnant. RESULTS: Overall, 33.2% of @entity1 took @entity1501 most days in the month before becoming pregnant, and 39.9% said that their pregnancy was unintended. Adolescent mothers were less likely to take periconceptional @entity1501 (9.2%) and more likely to report unintended pregnancy (62.0%) than older @entity1 . Overall, @entity1 who said that their pregnancy was intended were more likely to report that they had taken periconceptional @entity1501 (odds ratio: 4.75; 95% confidence interval: 3.16-7.14); after controlling for maternal age and income the odds ratio was 3.70 (95% confidence interval: 2.38-5.56). CONCLUSIONS: @entity1 whose pregnancies were intended were more likely to have been taking periconceptional @entity1501 than @entity1 whose pregnancies were unintended. The importance of fertile @entity1 's taking daily multivitamins that contain 400 microg (0.4 mg) of @entity1501 should be stressed among @entity1 who are not contemplating pregnancy, especially adolescents and low-income @entity1 .

Pregnancy intendedness and the use of periconceptional XXXX .

@entity1501 :: ('MESH:D005492', 'Chemical') :: ['folic acid'] @entity1 :: ('9606', 'Species') :: ['women', 'Women'] @entity601 :: ('MESH:D009436', 'Disease') :: ['neural tube defects'] @entity600 :: ('MESH:D000014', 'Disease') :: ['birth defects']
@entity1501 :: (MESH:D005492,Chemical) :: ['folic acid']
